Therapy Areas
PDS Biotechnology names senior vice president Business Development
19 May 2022 -

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines, announced on Wednesday that Sanjay Zaveri has joined PDS Biotech as senior vice president, Business Development.

Zaveri has extensive partnering experience having completed licenses and acquisitions between leading biotechnology and pharmaceutical companies. In the new role, he is responsible for business strategy, and managing the company's potential licensing and partnering opportunities in support of its pipeline. Prior to joining PDS Biotech he held the position of head of Business Development and Corporate Strategy at Strongbridge Biopharma, leading its business development, licensing and partnership strategy prior to its acquisition by Xeris Pharmaceuticals. Before Strongbridge, he held biotechnology consulting positions with Guidehouse, formerly Navigant Consulting, and IQVIA.

'We are pleased to have Sanjay join the PDS Biotech management team. He brings a great depth of experience successfully conducting business development in the life science industry, said PDS Biotech chief executive officer, Frank Bedu-Addo. 'As we demonstrate proof-of-concept for PDS0101 and our Versamune(R) and Infectimune platforms, Sanjay's proven ability to execute a sound business development strategy will be an asset to PDS Biotech.'